CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.

摘要: The remarkable advances in interferon-sparing, all-oral hepatitis C virus (HCV) treatment were a highlight of the 2014 Conference on Retroviruses and Opportunistic Infections (CROI). backbone nucleotide inhibitor sofosbuvir nonstructural protein 5A (NS5A) ledipasvir with an additional third agent (HCV protease or HCV nonnucleoside reverse transcriptase inhibitor) led to sustained virologic response (SVR) rate 12 weeks after cessation 95% 100% only 6 treatment. These results demonstrate potential combination directacting antiviral (DAA) therapy for abbreviated, well-tolerated, highly effective Two triple-drug regimens that comprised NS5A inhibitor, also resulted SVRs more than 90% patients genotype 1. HIV coinfection does not appear negatively impact DAA-based therapy, as evidenced by similar rates HIV/HCV-coinfected compared HCV-monoinfected receiving interferonsparing -containing regimens. There was continued emphasis at CROI non-AIDS complications infection, specifically cardiovascular disease, renal insufficiency, bone endocrine disorders persist among treated disease contribute morbidity mortality. Finally, new data novel drugs combinations tuberculosis (TB), patient outcomes using rapid TB diagnostics, short-course prevention strategy presented.